LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head &amp; neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy

Mach, Nicolas; Fernandez, Eugenio; Vernet, Rémi; Von Rohr, Olivier; Urwyler, Muriel; Charrier, Emily Pauline; Belkouch, Marie-Claude; Saingier, Valentin; Courtout, Fabien; De Vito, Claudio; Rubin, Olivier; Ancrenaz, Virginie; Grogg, Julien; Renaux, Jessica; Gysel, Katrin; Müller, Gisela; Brezina, Tomas; Rordorf, Tamara; Joerger, Markus; Michielin, Olivier

doi:10.1016/j.annonc.2023.10.040

Conference presentation

English

LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy

Presented atESMO Congress 2023, Madrid, 20-24 octobre 2023

Publication date2023-10

NotePublished in : Annals of Oncology, Volume 34, Supplement 2, 2023, Page S1286.

Affiliation entities

Research groups

Citation (ISO format)

MACH, Nicolas et al. LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy. In: ESMO Congress 2023. Madrid. 2023. doi: 10.1016/j.annonc.2023.10.040

Presentation

Summary

Identifiers

PID : unige:180151
DOI : 10.1016/j.annonc.2023.10.040

Additional URL for this publicationhttps://linkinghub.elsevier.com/retrieve/pii/S0923753423041844

127views

164downloads

Creation01/09/2024 18:34:35

First validation23/09/2024 08:08:36

Update13/10/2025 12:41:18

Status update08/10/2024 15:14:04

Last indexation24/11/2025 19:28:28

Archive ouverte UNIGE

LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy

Technical informations